http://orcid.org/0000-0002-5383-7934
Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Carlos Taxonera, Fernando de Andrés-Nogales, Santiago García-López, Amelia Sánchez-Guerrero, Belén Menchén, Carmen Peral, Ana Cábez, Susana Gómez, Alejandra López-Ibáñez de Aldecoa, Miguel Ángel Casado & Luis Menchén. (2022) Cost-effectiveness analysis of using innovative therapies for the management of moderate-to-severe ulcerative colitis in Spain. Expert Review of Pharmacoeconomics & Outcomes Research 22:1, pages 73-83.
Read now
Read now
Articles from other publishers (24)
Åsa H. Everhov, Jonas Söderling, Gustaf Befrits, Hamed Khalili, Gabriella Bröms, Martin Neovius, Johan Askling, Jonas Halfvarson, Jonas F. Ludvigsson & Ola Olén. (2023) Increasing healthcare costs in inflammatory bowel disease 2007–2020 in Sweden. Alimentary Pharmacology & Therapeutics 58:7, pages 692-703.
Crossref
Crossref
M Ellen Kuenzig, Stephanie Coward, Laura E Targownik, Sanjay K Murthy, Eric I Benchimol, Joseph W Windsor, Charles N Bernstein, Alain Bitton, Jennifer L Jones, Kate Lee, Juan-Nicolás Peña-Sánchez, Noelle Rohatinsky, Sara Ghandeharian, James H B Im, Rohit Jogendran, Saketh Meka, Jake Weinstein, Tyrel Jones May, Manisha Jogendran, Sahar Tabatabavakili, Elias Hazan, Malini Hu, Jessica Amankwah Osei, Rabia Khan, Grace Wang, Mira Browne, Tal Davis, Quinn Goddard, Julia Gorospe, Kate Latos, Kate Mason, Jack Kerr, Naji Balche, Anna Sklar & Gilaad G Kaplan. (2023) The 2023 Impact of Inflammatory Bowel Disease in Canada: Direct Health System and Medication Costs. Journal of the Canadian Association of Gastroenterology 6:Supplement_2, pages S23-S34.
Crossref
Crossref
Eun Young Park, Dong Hoon Baek, Gwang Ha Kim, Choongrak Kim, Hasung Kim, Jeong Woo Lee & Geun Am Song. (2023) Longitudinal trends in direct costs and healthcare utilization ascribable to inflammatory bowel disease in the biologic era: a nationwide, population‐based study. Journal of Gastroenterology and Hepatology 38:9, pages 1485-1495.
Crossref
Crossref
Shin Ju Oh, Hyo Jong Kim & Chang Kyun Lee. (2023) A dose‐dependent increase in the risk of inflammatory bowel disease after exposure to broad‐spectrum antibiotics: A national population study in Korea. Alimentary Pharmacology & Therapeutics 58:2, pages 191-206.
Crossref
Crossref
In Sub Han, Dong Hoon Baek, Seung Min Hong, Bong Eun Lee, Moon Won Lee, Gwang Ha Kim & Geun Am Song. (2023) Incidence and adverse clinical events of primary sclerosing cholangitis with ulcerative colitis. International Journal of Colorectal Disease 38:1.
Crossref
Crossref
Antonella Smeriglio, Daniele Marcoccia, Marcella Denaro & Domenico Trombetta. (2023) Nutraceuticals in the Treatment of Inflammatory Bowel Disease: How the Panorama has Changed in the Last Decade?. Current Medicinal Chemistry 30:19, pages 2165-2190.
Crossref
Crossref
Ke Lan, Huabing Yang, Junping Zheng, Haiming Hu, Tianxiang Zhu, Xiaojuan Zou, Baifei Hu & Hongtao Liu. (2023)
Poria cocos
oligosaccharides ameliorate dextran sodium sulfate-induced colitis mice by regulating gut microbiota dysbiosis
. Food & Function 14:2, pages 857-873.
Crossref
Crossref
Ting Liu, Zunxi Ning, Pengyu Liu & Huiyuan Gao. (2023) Cassane diterpenoid ameliorates dextran sulfate sodium-induced experimental colitis by regulating gut microbiota and suppressing tryptophan metabolism. Frontiers in Immunology 13.
Crossref
Crossref
Liselot W van Erp, Myrte K Neijenhuis, Wendy Heida, Joost Derwig, Caroline E Geleijns, Marcel J M Groenen & Peter J Wahab. (2022) Improving Care for Recently Diagnosed Inflammatory Bowel Disease Patients: Lessons Learned From a Patient-Centred, Mixed-Method Study. Journal of Crohn's and Colitis 16:5, pages 737-745.
Crossref
Crossref
Sulmaz Ghahramani, Zahra Tamartash, Mohammad Sayari, Homayoun Vahedi, Fatemeh Karimian, Sadegh Heydari & Kamran Bagheri Lankarani. (2022) Risk Factors Affecting 90-day Readmission of Patients with Inflammatory Bowel Disease. Middle East Journal of Digestive Diseases 14:1, pages 34-43.
Crossref
Crossref
Wenqi Shan, Wenzhe Zhang, Fei Xue, Yongbin Ma, Liyang Dong, Ting Wang, Yu Zheng, Dingqi Feng, Ming Chang, Guoyue Yuan & Xuefeng Wang. (2021) Schistosoma japonicum peptide SJMHE1 inhibits acute and chronic colitis induced by dextran sulfate sodium in mice. Parasites & Vectors 14:1.
Crossref
Crossref
Ju-Young Shin, Hye-Min Park, Min-Young Lee, Ja-Young Jeon, Hyun-Jeong Yoo & Byong Duk Ye. (2021) Real-World Incidence of Suboptimal Response to Anti-Tumor Necrosis Factor Therapy for Ulcerative Colitis: A Nationwide Population-Based Study. Gut and Liver 15:6, pages 867-877.
Crossref
Crossref
Reinier Cornelis Anthonius van Linschoten, Elyke Visser, Christa Diana Niehot, C. Janneke van der Woude, Jan Antonius Hazelzet, Desirée van Noord & Rachel Louise West. (2021) Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents. Alimentary Pharmacology & Therapeutics 54:3, pages 234-248.
Crossref
Crossref
Siew C Ng, Joyce Wing Yan Mak, Partha Pal & Rupa Banerjee. (2020) Optimising management strategies of inflammatory bowel disease in resource-limited settings in Asia. The Lancet Gastroenterology & Hepatology 5:12, pages 1089-1100.
Crossref
Crossref
Yoon Suk Jung, Minkyung Han, Sohee Park & Jae Hee Cheon. (2020) Impact of early anti-TNF use on clinical outcomes in Crohn’s disease: a nationwide population-based study. The Korean Journal of Internal Medicine 35:5, pages 1104-1113.
Crossref
Crossref
Benjamin Click, Rocio Lopez, Susana Arrigain, Jesse Schold, Miguel Regueiro & Maged Rizk. (2020) Shifting Cost-drivers of Health Care Expenditures in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 26:8, pages 1268-1275.
Crossref
Crossref
Chang Kyun Lee, Hyo Jung Ha, Shin Ju Oh, Jung‐Wook Kim, Jung Kuk Lee, Hyun‐Soo Kim, Soon Man Yoon, Sang‐Bum Kang, Eun Soo Kim, Tae Oh Kim, Soo‐Young Na, Jun Lee, Sang‐Wook Kim, Hoon Sup Koo, Byung Kyu Park, Han Hee Lee, Eun Sun Kim, Jae Jun Park, Min Seob Kwak, Jae Myung Cha, Byong Duk Ye, Chang Hwan Choi & Hyo Jong Kim. (2019) Nationwide validation study of diagnostic algorithms for inflammatory bowel disease in Korean National Health Insurance Service database. Journal of Gastroenterology and Hepatology 35:5, pages 760-768.
Crossref
Crossref
Ashwin N. Ananthakrishnan, Gilaad G. Kaplan & Siew C. Ng. (2020) Changing Global Epidemiology of Inflammatory Bowel Diseases: Sustaining Health Care Delivery Into the 21st Century. Clinical Gastroenterology and Hepatology 18:6, pages 1252-1260.
Crossref
Crossref
Karma Yeshi, Roland Ruscher, Luke Hunter, Norelle L. Daly, Alex Loukas & Phurpa Wangchuk. (2020) Revisiting Inflammatory Bowel Disease: Pathology, Treatments, Challenges and Emerging Therapeutics Including Drug Leads from Natural Products. Journal of Clinical Medicine 9:5, pages 1273.
Crossref
Crossref
Martin Maronek, Rene Link, Lubos Ambro & Roman Gardlik. (2020) Phages and Their Role in Gastrointestinal Disease: Focus on Inflammatory Bowel Disease. Cells 9:4, pages 1013.
Crossref
Crossref
Yoon Suk Jung. (2020) Trends in Healthcare Costs for Inflammatory Bowel Disease in South Korea. Gut and Liver 14:1, pages 3-4.
Crossref
Crossref
Jie-Hyun KimHyunsoo ChungHyun-Soo Kim, Su Young KimJae Myung ChaChang Kyun LeeByung Kyu ParkSohee Park. (2020) Research Using Big Data in Gastroenterology: Based on the Outcomes from Big Data Research Group of the Korean Society of Gastroenterology. The Korean Journal of Gastroenterology 75:1, pages 4.
Crossref
Crossref
Joyce WY Mak & Joseph JY Sung. (2019) The Use of Biologics and Biosimilar in Asian patients with IBD: Are we ready?. Journal of Gastroenterology and Hepatology 34:8, pages 1269-1270.
Crossref
Crossref
Soo-Young Na. (2019) Asian Physician's Perspectives on Biosimilars in Inflammatory Bowel Disease: Are We Ready to Use?. The Korean Journal of Gastroenterology 74:6, pages 301.
Crossref
Crossref